INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

About this update from Inovio Pharmaceuticals, Inc.

[{"type":"list","items":[{"val":[{"type":"text","content":"On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025","length":172,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25","length":131,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":131,"olType":false}]},{"val":[{"type":"text","content":"Clinical and immunological results from Phase 1/2 trial of INO-3107 published in Nature Communications in February 2025","length":119,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with significant clinical benefit as measured by reduced need for surgery","length":181,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":181,"olType":false}]},{"val":[{"type":"text","content":"Announced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encoded monoclonal antibodies (DMAbs) were well tolerated and exhibited long-lasting in vivo production","length":195,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Preprint manuscript available on ResearchSquare.com ","length":56,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":56,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":854,"olType":false},{"type":"text","content":"PLYMOUTH MEETING, Pa., May 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2025 and provided an update on recent company developments.","length":369,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":129,"url":"https://media.zenfs.com/en/prnewswire.com/02f6eff2e3f0f811a2f544c30d57cb0d"},"resized":{"url":"https://s.yimg.com...

More updates from Inovio Pharmaceuticals, Inc.